Streetbeat News

Stock Prices

CASI

HC Wainwright & Co. has reaffirmed its Buy rating on CASI Pharmaceuticals (NASDAQ:CASI), increasing the price target from $10.00 to $12.00. CASI's stock has risen 1.33% to $4.56 in the last 24 hours. The new price target suggests a potential upside of 163.16%. CASI focuses on commercializing therapeutics for leukemias, lymphomas, and multiple myeloma, with EVOMELA being a key revenue driver.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 5:00 pm

ALPN

Alpine Immune Sciences (NASDAQ:ALPN) received 10 analyst ratings in the last quarter, with an average price target of $21.6, representing significant upside from the current price of $12.4. The consensus shows 3 bullish, 7 somewhat bullish, and no bearish ratings. The average price target has increased by 25.22% from the previous target of $17.25.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 5:00 pm

CABA

Cantor Fitzgerald has reaffirmed its Overweight rating on Cabaletta Bio (NASDAQ:CABA) and increased its price target from $40.00 to $50.00. Cabaletta Bio's shares have risen 1.66% to $17.76. The new price target suggests a potential upside of 181.53%. Cabaletta Bio is a clinical-stage biotech company developing engineered T cell therapies for B cell-mediated autoimmune diseases.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 5:00 pm

VEEV

Truist Securities has maintained a Hold rating on Veeva Systems (NYSE:VEEV) but lowered its price target from $227.00 to $187.00. Veeva Sys shares are currently trading up 3.7% at $179.88, and the new price target suggests a potential upside of 3.96%. Veeva is a leading provider of cloud-based software for the life sciences industry, with products like Veeva CRM and Veeva Vault.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 5:00 pm

CI

Over the past 15 years, Cigna Group (NYSE:CI) has produced an average annual return of 26.02%, outperforming the market. A $1000 investment in CI 15 years ago would be worth $26,202.21 today. Cigna Group currently has a market cap of $85.02 billion.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 5:00 pm

WKME

BMO Capital has maintained its Market Perform rating for WalkMe Ltd (NASDAQ:WKME) and increased its price target from $9.50 to $11.00. WalkMe's shares are currently trading at $9.88, and the new price target suggests an 11.34% upside potential. WalkMe is a cloud-based digital adoption platform with significant revenue from the U.S.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 5:00 pm

ONON

Telsey Advisory Group has maintained its Outperform rating for On Holding AG (NYSE:ONON) but reduced its price target from $40.00 to $37.00. Despite the lower price target, the new target suggests a significant upside of 42.03% from the current price of $26.05. On Holding, a premium performance sports brand, does not manufacture its products but relies on third-party suppliers and contract manufacturers, with most of its revenue coming from North America.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 5:00 pm

FICO

Over the past 10 years, Fair Isaac (NYSE:FICO) has delivered an average annual return of 33.48%, outperforming the market by 23.83%. A $100 investment in FICO a decade ago would be worth $1,786.72 today. Fair Isaac currently has a market cap of $25.38 billion.

Portfolio Pulse from Benzinga Insights

November 15, 2023 | 5:00 pm

DIS

Disney's stock (DIS) is trading higher after reports emerged that activist investor ValueAct is accumulating a stake in the company. This move by ValueAct could signal confidence in Disney's future prospects or potential for strategic changes that could benefit shareholders.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 4:58 pm

JMIA

Jumia Technologies AG (NYSE:JMIA) reported a Q3 FY23 sales decline of 11.1% Y/Y to $44.9 million, missing analyst expectations. Orders, active consumers, TPV, and GMV all saw significant year-over-year decreases. However, gross profit margin improved slightly, and operating loss and adjusted EBITDA loss narrowed significantly due to cost savings. The company revised its FY23 adjusted EBITDA loss guidance to a narrower range. JMIA shares rose 8.68% to $2.86 following the report.

Portfolio Pulse from Lekha Gupta

November 15, 2023 | 4:58 pm